Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset
15.1.2024 14:28:00 CET | Business Wire | Press Release
Neuraptive Therapeutics Inc., a leader in innovative medical solutions, is pleased to announce that it has received Orphan Drug Designation from the United States (US) Food and Drug Administration (FDA) for its fusogen contained in the NTX-001 treatment kit. This designation marks a significant milestone in developing NTX-001, a novel treatment for peripheral nerve injury requiring repair.
Dr. Seth Schulman, Chief Medical Officer of Neuraptive Therapeutics Inc., stated, “Receiving the Orphan Drug Designation for NTX-001 is a testament to our commitment to advancing healthcare solutions for patients impacted by peripheral nerve injuries who today have limited options.” The Orphan Drug Designation is granted to drugs intended to treat rare diseases or conditions in the US.
Highlights of Orphan Designation are:
- 7-year marketing exclusivity to sponsors of approved orphan products
- Federal tax credit for expenses incurred in conducting clinical research within the United States
- Waiver of Prescription Drug User Fee Act (PDUFA) fees for orphan drugs
- Ability to qualify to compete for research grants from the Office of Orphan Products Development (OOPD) to support clinical studies for orphan drugs
- Eligibility to receive regulatory assistance and guidance from the FDA in the design of an overall drug development plan.
“The Granting of orphan drug designation by the FDA comes at an important time, as we prepare to meet with regulators in the coming months to seek their input on the future development work and the ultimate path to approval, “ said Evan L. Tzanis, Chief Operating Officer and EVP of R&D. “ Following this designation, Neuraptive Therapeutics plans to accelerate the development of NTX-001, aiming to bring this promising treatment to patients as soon as possible.” Said Mr. Tzanis.
For more information about Neuraptive Therapeutics, Inc., and our work in peripheral nerve injury treatments, please visit Neuraptive.com.
About NTX-001
NTX-001 is the only surgical technology that may rapidly improve functional outcomes in patients with peripheral nerve injuries by preventing Wallerian degeneration after PEG-fusing severed axons using an optimized and specific treatment sequence in a controlled nerve isolation chamber.
About Neuraptive Therapeutics, Inc.:
Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company is headquartered in Wayne, PA. For more information, see www.neuraptive.com.
This press release contains forward-looking statements that are subject to risks and uncertainties. Due to various factors, actual results may differ materially from those indicated in the forward-looking statements. The Company disclaims any obligation to update or revise forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240115132196/en/
Contact information
IR@neuraptive.com
or
+1-484-787-3203
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
South African Agency Boundless Delivers Mazda’s First AI-produced Commercial Using Luma Agents15.4.2026 21:07:00 CEST | Press Release
Luma AI today announced that Boundless, an independent creative agency based in Johannesburg, South Africa, has produced Mazda’s first AI-produced commercial using Luma Agents, Luma’s AI-powered creative workflow system. Delivered in less than two weeks from initial brief to final approval, the project marks a significant step in the use of AI-native workflows for commercial production. As part of the collaboration, Boundless has also signed an agreement with Luma to integrate the company’s AI technologies into its creative workflow across future client work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415098939/en/ The project marks a milestone for both Boundless and the broader advertising industry, demonstrating how AI-native workflows can help agencies compress production timelines while maintaining creative quality, brand consistency, and operational oversight. The campaign supports the re-entry of the Mazda MX-5
Chaired by HRH Crown Prince, PIF Board of Directors Approves PIF 2026-2030 Strategy15.4.2026 17:29:00 CEST | Press Release
The Board of Directors ofPIF, chaired by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince, Prime Minister and Chairman of the Board of Directors of PIF, has approved PIF’s 2026-2030 strategy, which is a continuation of PIF’s long-term strategy. The strategy will focus on delivering competitive domestic ecosystems to connect sectors, unlock the full potential of strategic assets, maximize long-term returns, and continue to drive the economic transformation of Saudi Arabia and further enhance the quality of life of its citizens. The 2026-2030 strategy marks a natural evolution as PIF moves from a period of rapid growth and acceleration to a new phase of sustained value creation, with a strengthened focus on maximizing impact, raising the efficiency of investments, and applying the highest standards of governance, transparency and institutional excellence. In addition, PIF will further enable the role of the private sector as an effective partner for susta
Chaired by HRH Crown Prince, PIF Board of Directors Approves PIF 2026-2030 Strategy15.4.2026 17:29:00 CEST | Press Release
The Board of Directors ofPIF, chaired by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince, Prime Minister and Chairman of the Board of Directors of PIF, has approved PIF’s 2026-2030 strategy, which is a continuation of PIF’s long-term strategy. The strategy will focus on delivering competitive domestic ecosystems to connect sectors, unlock the full potential of strategic assets, maximize long-term returns, and continue to drive the economic transformation of Saudi Arabia and further enhance the quality of life of its citizens. The 2026-2030 strategy marks a natural evolution as PIF moves from a period of rapid growth and acceleration to a new phase of sustained value creation, with a strengthened focus on maximizing impact, raising the efficiency of investments, and applying the highest standards of governance, transparency and institutional excellence. In addition, PIF will further enable the role of the private sector as an effective partner for susta
New Method Enables Structural Determination of Diverse Phenolic Compounds from a Tiny Alpine Flower Sample15.4.2026 16:00:00 CEST | Press Release
Hyuga Hirano (United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, and collaborative graduate student at the National Museum of Nature and Science (President: Makoto Manabe)); Takashi Kikuchi (Application Laboratories, Global Product Unit, Rigaku Corporation, a group company of Rigaku Holdings); Futa Sakakibara (Technical Advisor, R&D Support Division, Asterism G.K.); Yoshinori Murai (Senior curator, Department of Botany, National Museum of Nature and Science); and colleagues have successfully determined the structures of more than ten phenolic glycosides from a tiny sample of an alpine plant flower by developing a trace analysis method. This achievement is particularly significant because alpine plants are typically small and difficult to collect due to legal, ethical, and environmental considerations, resulting in extremely limited sample availability. Determining the structures of numerous chemical components from such a small sample repres
New Method Enables Structural Determination of Diverse Phenolic Compounds from a Tiny Alpine Flower Sample15.4.2026 16:00:00 CEST | Press Release
Hyuga Hirano (United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, and collaborative graduate student at the National Museum of Nature and Science (President: Makoto Manabe)); Takashi Kikuchi (Application Laboratories, Global Product Unit, Rigaku Corporation, a group company of Rigaku Holdings); Futa Sakakibara (Technical Advisor, R&D Support Division, Asterism G.K.); Yoshinori Murai (Senior curator, Department of Botany, National Museum of Nature and Science); and colleagues have successfully determined the structures of more than ten phenolic glycosides from a tiny sample of an alpine plant flower by developing a trace analysis method. This achievement is particularly significant because alpine plants are typically small and difficult to collect due to legal, ethical, and environmental considerations, resulting in extremely limited sample availability. Determining the structures of numerous chemical components from such a small sample repres
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom